Core Viewpoint - The article discusses the ongoing debate in the capital market regarding the valuation and relevance of hyaluronic acid, with Huaxi Biological refuting claims that it is outdated, labeling such views as a product of "restless capital" [1][3][9]. Group 1: Company Positioning - Huaxi Biological published an article on May 17, 2023, directly criticizing nine brokerage reports that suggested hyaluronic acid is outdated, asserting that this narrative is misleading and harmful to the industry [1][3]. - The company emphasized the importance of voicing its stance to protect the integrity of the hyaluronic acid industry, which has been developed over decades of scientific research [6][9]. - Huaxi Biological's market share in the global hyaluronic acid market was reported at 44% in 2021, with China accounting for 82% of global sales [6]. Group 2: Market Dynamics - The article highlights a shift in capital market interest from hyaluronic acid to recombinant collagen, with companies like Juzhibio gaining significant market traction [10][15]. - Juzhibio's stock price has surged nearly 70% in 2023, positioning it as a leading player in the beauty and skincare sector, while Huaxi Biological and other hyaluronic acid companies have seen declining performance [10][13]. - The market for recombinant collagen is projected to grow at a compound annual growth rate (CAGR) of 44.93%, reaching 585.7 billion yuan by 2025 [16]. Group 3: Industry Trends - The article notes that the beauty and skincare industry is experiencing rapid shifts, with companies needing to adapt to changing consumer preferences and capital market trends [2][15]. - Huaxi Biological has begun to diversify its product offerings, launching multiple collagen products and obtaining medical device registrations to stay competitive [17]. - The competitive landscape for recombinant collagen is intensifying, with various companies entering the market, indicating that maintaining a leading position will be challenging for Juzhibio [16][17].

Group 1 - The article discusses the challenges faced by the hyaluronic acid (HA) industry, claiming it has been misrepresented and undermined in recent years due to misleading narratives in the capital market [2][6] - Huaxi Biological specifically names several securities firms and their reports that have contributed to the negative perception of HA, including Huatai Securities and Anxin Securities [2][5][7] - The company argues that the rise of the "outdated" narrative surrounding HA is a result of a capital market phenomenon that seeks to shift focus to new investment themes, thereby undermining established industries [6][8] Group 2 - Huaxi Biological highlights the significant growth of competitor Juzhi Biological, which reported a revenue of 5.539 billion yuan in 2024, a year-on-year increase of 57.07%, and a net profit of 2.062 billion yuan, up 42.06% [5][10] - The company emphasizes its own historical performance, noting that from 2018 to 2022, it experienced substantial revenue and profit growth, with annual revenue growth rates exceeding 87% and net profit growth rates surpassing 90% [10] - However, Huaxi Biological has faced a sharp decline in performance recently, with a projected revenue of 5.371 billion yuan and a net profit of 174 million yuan in 2024, representing year-on-year decreases of 11.61% and 70.59% respectively [10][11] Group 3 - The company is undergoing significant internal reforms, described as a "bone-scraping" process, initiated by the chairman to address management issues and improve operational efficiency [10][11] - The article indicates that Huaxi Biological is currently facing both internal challenges due to its restructuring efforts and external pressures from competition in the market [11]

针对突然向券商"开炮"，A股医美巨头华熙生物（688363.SH，股价53.21元，市值256.3亿元）作出最新 回应。 今日（5月20日）午间，华熙生物方面向《每日经济新闻》记者发来独家回应。在回应中，华熙生物表 示："透明质酸是中国在全球占据第一份额的优势产业，涉及到科研、医疗、医美、美妆、营养健康等 多个生命健康的相关领域，因此整个透明质酸产业都一直希望华熙生物作为行业龙头可以带头发声，纠 正近年来针对透明质酸这一生命科学关键物质的罔顾科学的踩踏和抹黑。" 5月19日晚间，华熙生物在其官方微信号发布《概念总在重演，科技永远向前》的文章，对市场上流行 的"玻尿酸过时"的观点，进行了点名驳斥。 《每日经济新闻》记者注意到，华熙生物在文章中点名几家券商机构称，2022年开始，随着资本市场不 断追求新的公司题材，重组胶原蛋白概念被看似幸运地选中了。为了营造比透明质酸产业更大的预期， 围绕某重组胶原企业的研报中，出现了大量直接针对中国透明质酸产业的所谓"对比研究"。 文章称，透明质酸"过时论"的兴起，本质上是一场由"浮躁资本"构建的题材幻象，试图用"神话过时"绕 开中国产业发展必然面临的进阶过程，引导资本和市场资 ...

Group 1: Industry Initiatives - The China Fragrance and Cosmetic Industry Association and the China Association of Plastic Surgery jointly released a health ecosystem initiative for the medical beauty and cosmetics industry, emphasizing the importance of scientific rigor and rational guidance in product efficacy [1] - The initiative calls for promoting public understanding through scientific education and collaboration with authoritative institutions to enhance public awareness of technological paths [1] - It advocates for innovation and diversity in the industry, encouraging cooperation in ingredient innovation, formula optimization, and process breakthroughs [1] - The initiative stresses the need for civilized marketing and honest promotion, aiming to establish objective and fair marketing practices as industry norms [1] - It proposes the establishment of an industry self-discipline system and a self-discipline alliance to evaluate and publicly disclose results of any misleading or uncivil behavior [1] Group 2: Company Positioning - Huaxi Biological published an article addressing misleading conclusions regarding the comparison between collagen and hyaluronic acid, which have been widely circulated in the media [2] - The company clarified that its concerns about collagen products primarily relate to the exaggerated claims of topical collagen skincare products, emphasizing that effective collagen products require injection [2][3] - Huaxi Biological's strategy focuses on leveraging hyaluronic acid to develop synthetic biological capabilities, exploring effective substances in life sciences, while maintaining a unified strategic logic [3] - The company has not promoted collagen as a mainstream technology in consumer products due to insufficient scientific evidence supporting its efficacy in managing aging compared to hyaluronic acid [3] - Huaxi Biological believes that the extracellular matrix (ECM) is the comprehensive research and industrial transformation direction that includes all key substances like hyaluronic acid, collagen, and elastin [3]

登录新浪财经APP 搜索【信披】查看更多考评等级 注：除上表所示修订内容外，统一将"股东大会"改为"股东会"、"或"改为"或者"、条款号及章节号相应 修改。 本次公司章程修订事项尚需提交股东大会审议，《华熙生物科技股份有限公司章程（2025年5月修 订）》（以下简称"修订版公司章程"）自股东大会审议通过之日起生效，原章程自修订版公司章程生效 之日起废止，同时提请股东大会授权公司管理层向市场监督管理部门办理修订版公司章程的变更登记等 相关手续，并根据市场监督管理部门意见对修订版公司章程进行必要文字调整。 三、公告附件 1、《华熙生物科技股份有限公司章程（2025年5月修订）》； 2、《华熙生物科技股份有限公司股东会议事规则（2025年5月修订）》； 3、《华熙生物科技股份有限公司董事会议事规则（2025年5月修订）》； 4、《华熙生物科技股份有限公司独立董事工作制度（2025年5月修订）》； 5、《华熙生物科技股份有限公司利润分配管理制度（2025年5月修订）》； 6、《华熙生物科技股份有限公司关联交易决策制度（2025年5月修订）》； 7、《华熙生物科技股份有限公司募集资金管理制度（2025年5月修订）》； ...

证券代码：688363 证券简称：华熙生物 公告编号：2025-019 华熙生物科技股份有限公司 关于董事会换届选举的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 华熙生物科技股份有限公司（以下简称"公司"）第二届董事会任期已届满， 根据《中华人民共和国公司法》（以下简称"《公司法》"）、《上海证券交易 所科创板股票上市规则》等法律、法规以及《华熙生物科技股份有限公司章程》 （以下简称"《公司章程》"）的相关规定，公司开展董事会换届选举工作，现 将本次董事会换届提名情况公告如下： 一、 董事会换届提名情况 根据公司章程的规定，公司控股股东华熙昕宇投资有限公司提名赵燕女士、 郭珈均先生、李亦争先生、汪卉先生、于静女士、陈玉鑫先生为公司第三届董事 会非独立董事（候选人简历详见附件）；提名姚洋先生、陈达亮先生、徐文鸣先 生为公司第三届董事会独立董事候选人（候选人简历详见附件），独立董事候选 人姚洋先生、陈达亮先生、徐文鸣先生已参加独立董事培训，并取得上海证券交 易所认可的相关培训证明材料，其中陈达亮先生为会计专业人士。 公司 ...

华熙生物科技股份有限公司 内部审计制度 （2025 年 5 月） 第一章 总则 第一条 为规范华熙生物科技股份有限公司（以下简称"公司"或"本 公司"）的内部审计工作，发挥内部审计在强化内部控制、改善风险管理、 完善公司治理结构、促进公司目标实现的作用，保护公司及股东的合法权益， 依据《中华人民共和国审计法》、《上海证券交易所科创板上市公司自律监 管指引第 1 号——规范运作》、《内部审计基本准则》、《企业内部控制 基本规范》等相关法律、法规、规范性文件和《华熙生物科技股份有限公司 章程》（以下简称"《公司章程》"）的规定，结合公司实际情况，制定本 制度。 第二条 本制度所称内部审计，是公司内部独立、客观的确认和咨询活 动，旨在增加企业价值和改善运营。通过系统化、规范化的方法，评价并改 善风险管理、财务信息、内部控制和治理过程的效果，帮助公司实现经营目 标。 本制度所称内部控制，是指公司董事会、高级管理人员及其他有关人员 实施的、旨在实现控制目标的过程。内部控制的目标是合理保证公司经营管 理合法合规、资产安全、财务报告及相关信息真实完整，提高经营效率和效 果，促进企业实现发展战略。 第三条 内部审计对董事会负 ...

General Overview - The document outlines the management system for the shares held by the directors, senior management, and core technical personnel of Huaxi Biological Technology Co., Ltd. [1] Shareholding Management - The system is established in accordance with various laws and regulations, including the Company Law and Securities Law of the People's Republic of China [1] - It applies to the management of shares held by the company's directors, senior management, and core technical personnel [1] Trading Restrictions - Directors and senior management must be aware of laws prohibiting insider trading, market manipulation, and short-term trading before buying or selling shares [2] - They are prohibited from engaging in margin trading using the company's shares as the underlying security [2] Share Transfer Rules - There are specific circumstances under which shares held by directors and senior management cannot be transferred, including ongoing investigations or penalties related to securities violations [3] - Trading is restricted during certain periods, such as 15 days before the annual and semi-annual reports, and 5 days before quarterly reports [4] Reporting and Disclosure - The company secretary is responsible for managing the data and information regarding the shareholdings of directors and senior management, ensuring compliance with reporting requirements [11] - Any changes in shareholdings must be reported within two trading days, including details such as the number of shares held before and after the change [10] Penalties for Violations - Violations of the trading rules may result in the company recovering profits made from illegal trades and disclosing the situation publicly [12] - Serious violations can lead to penalties from the China Securities Regulatory Commission, including market bans for responsible individuals [13] Additional Provisions - The document specifies that any matters not covered will be governed by relevant national laws and regulations [14] - The management system will take effect upon approval by the company's board of directors, replacing any previous regulations [14]

华熙生物科技股份有限公司 关于修订公司章程及新增、修订或废止部分制度细则 的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 华熙生物科技股份有限公司（以下简称"公司"）于 2025 年 5 月 16 日召开 第二届董事会第十九次会议，审议通过了《关于取消监事会、修订 <公司章程> 并办理工商变更登记的议案》 《关于修订部分公司管理制度的议案》 证券代码：688363 证券简称：华熙生物 公告编号：2025-018 《关于修订或 废止部分公司管理制度、细则的议案》 《关于制定 <华熙生物科技股份有限公司内> 部审计制度>的议案》，现将具体情况公告如下： 一、 本次修订公司章程及新增、修订或废止部分制度细则的概况 根据《中华人民共和国公司法（2023 年修订）》（以下简称"《公司法》"）、 中国证券监督管理委员会发布的《上市公司章程指引（2025 年修订）》（以下简 称"《章程指引》"）等法律法规、部门规章的规定，公司拟取消监事会，由董事 会审计委员会行使《公司法》规定的监事会的职权，同时由董事会薪酬与考核委 员会承接《 ...

华熙生物科技股份有限公司 第四条 公司控股股东、实际控制人不得向公司指定会计师事务所，不得干 预公司审计委员会、董事会及股东会独立履行审核职责。 第二章 会计师事务所执业质量要求 第五条 公司选聘的会计师事务所应当具备下列条件： (一) 具有独立的主体资格，具备国家行业主管部门和中国证监会规定的开 展证券期货相关业务所需的执业资格； (二) 具有固定的工作场所、健全的组织机构和完善的内部管理和控制制度； 第一章 总则 第一条 为规范华熙生物科技股份有限公司（以下简称"公司"）选聘（含 "续聘"、"改聘"，下同）会计师事务所的行为，提高审计工作和财务信息的 质量，切实维护股东利益，根据《中华人民共和国公司法》《国有企业、上市公 司选聘会计师事务所管理办法》《上海证券交易所科创板股票上市规则》《上海 证券交易所科创板上市公司自律监管指引第 1 号——规范运作》《华熙生物科技 股份有限公司章程》（以下简称"《公司章程》"）等有关规定，结合公司实际 情况，制定本制度。 第二条 本制度所称选聘会计师事务所，是指公司根据相关法律法规要求， 聘任会计师事务所对财务会计报告发表审计意见、出具审计报告的行为。公司聘 任会计师事 ...